Therapeutic effects of α-adrenergic receptor antagonists on benign prostatic hyperplasia: a network meta-analysis
Wang, X.-P.
Zhonghua Nan Ke Xue 24(3): 247-253
2018
ISSN/ISBN: 1009-3591 PMID: 30161312 Document Number: 695957
目的： 探究常用选择性α肾上腺素能受体拮抗剂治疗良性前列腺增生（BPH）的药物疗效。方法： 通过检索PubMed、Embase和CNKI数据库，筛选选择性α肾上腺素能受体拮抗剂治疗BPH的国内外相关文献，提取有关治疗过程中患者发生各种常见不良反应的信息，通过多变量meta分析探索不同α肾上腺素能受体拮抗剂的治疗效果。结果： 共检索237篇相关文献，最终纳入研究13篇。特拉唑嗪和坦索洛新的总不良反应发生率最高，分别是51.9%和34.0%，其中以头痛、虚弱无力和眩晕为发生率最高的不良反应，平均发生率分别约为38.3%、23.6%和17.5%。此外，坦索洛新对BPH患者的性功能方面的影响也居于首位（70.4%）。结论： 多沙唑嗪可以作为BPH患者的首选治疗药物，提高治疗效果及生活质量，而特拉唑嗪和坦索洛新需要根据患者对不同不良反应的耐受性选择性应用。.
Document emailed within 1 workday
Related Documents
Ding, M.; Nian, Y.-q.; Hu, S.-b.; Yi, L.; Chen, F.-z.; Peng, M.; Wang, Y.-h. 2015: Safety and effectiveness of GreenLight 120-W laser photoselective vaporization of the prostate for benign prostatic hyperplasia: a meta-analysis Zhonghua Nan Ke Xue 21(7): 646-654Yu, H.J.; Chiu, T.Y.; Lai, M.K. 1995: Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial Journal of the Formosan Medical Association 94(1-2): 37-41
Maygarden, S.J.; Strom, S.; Ware, J.L. 1992: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia Archives of Pathology and Laboratory Medicine 116(3): 269-273
Isa Kroon, W.A.; Robles García, J.E. 1993: Therapeutic alternatives in benign prostatic hyperplasia Medicina Clinica 101(2): 64-66
Sivkov, A.V.; Egorov, A.A.; Romikh, V.V.; Surikov, V.N. 2002: Urodynamic criteria of predicting efficacy of therapy with alpha1-adrenergic blockaders in patients with benign prostatic hyperplasia Urologiia 2002(5 Suppl): 13-22
Schulze, H.; Berges, R.; Paschold, K.; Senge, T. 1992: New conservative therapeutic approaches in benign prostatic hyperplasia Der Urologe. Ausg. a 31(1): 8-13
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111
Yang, G.-Q.; Li, S.-W.; Zheng, H.; Zhang, W.-B.; Hu, W.-L.; Zheng, X.-M. 2009: Expression of estrogen receptor beta in benign prostatic hyperplasia complicated by chronic prostatitis Zhonghua Nan Ke Xue 15(4): 314-317
Wu, X.-j.; Yang, L.-y.; Zhang, X.-z. 2008: A clinical analysis of benign prostatic hyperplasia with chronic prostatitis Zhonghua Nan Ke Xue 14(6): 527-529
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Granados Loarca, E.A.; Chéchile Toniolo, G.; Villavicencio Mavrich, H. 1996: LH-RH agonists as therapeutic alternative in patients with benign prostatic hyperplasia (BPH) and surgical contraindication. Long term follow up Archivos Espanoles de Urologia 49(9): 923-927
Djavan, B.; Madersbacher, S.; Klingler, H.C.; Ghawidel, K.; Basharkhah, A.; Hruby, S.; Seitz, C.; Marberger, M. 1999: Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia Techniques in Urology 5(1): 12-20
Alver, J.E.; Mooppan, U.M.; Kester, R.R.; Gintautas, J.; Abadir, A.R.; Kim, H. 1989: The effects of the alpha 1-adrenergic antagonists terazosin and phentolamine on prostatic adenoma and urethra in vitro Proceedings of the Western Pharmacology Society 32: 317-325
Tomita, M.; Egawa, S.; Ikemoto, I.; Nakajo, H.; Hatano, T.; Kira, S.; Mizuo, T.; Kagami, Y. 2009: One-week effects of Tamsulosin on benign prostatic hyperplasia assessed with a daily symptom score Hinyokika Kiyo. Acta Urologica Japonica 55(4): 193-197
Zhang, Y.-g.; Wang, J.-y.; Liu, M.; Wan, B.; Wei, D.; Deng, S.-m.; Xu, J.; Wu, J.-y.; Chu, X.; Zeng, P. 2008: Data analysis of the objective observation parameters of benign prostatic hyperplasia patients accepting different treatment regimens Zhonghua Yi Xue Za Zhi 88(24): 1690-1692
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Kletscher, B.A.; Oesterling, J.E. 1995: Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 423-430
Gu, F. 2000: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China Chinese Medical Journal 113(4): 299-302
Denti, L.; Pasolini, G.; Cortellini, P.; Sanfelici, L.; Benedetti, R.; Cecchetti, A.; Ferretti, S.; Banchini, A.; Ablondi, F.; Valenti, G. 1999: Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH) Journal of Endocrinological Investigation 22(10 Suppl): 70-71
Blanc, M.; Sacrini, A.; Avogadro, A.; Gattamorta, M.; Lazzerini, F.; Gattoni, F.; Cretti, F. 1998: Prostatic volume: suprapubic versus transrectal ultrasonography in the control of benign prostatic hyperplasia La Radiologia Medica 95(3): 182-187